For example, in breast cancer, the poor expression of ASMTL-AS1 was tightly linked with advanced stage and poor prognosis, and ASMTL-AS1 overexpression might inactivate the oncogenic Wnt/β-catenin pathway and subsequently retard breast cancer progression in vitro and in vivo [11]. Here, ASMTL is linked to breast cancer.